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= 0,001), and Si (r = -0,58, p = 0,008), but not with TBF, In pooled SubleCtS, 
St emerged as the strongesl predictor of plasma leptin levels (SC - 0 42, 
p = 0017), tndel0ondently of IVGTT insulin ($C = 0.34, p = 0055) and TBF 
(SC = 0.if ,  NS; iotnt R *~ = 051, p ~ 0001), 
Conc/us/ons Pohenls w!th CHF have elevated plasma leptin concentm- 
tlona, In CHF. pllem8 Mpttn levels am IX~ttively related to plasma insulin 
and Invef~ly related to lnaulin eensitlvity. These relationships may be of 
I~P~,~lttlk= illlgOffance (n the incro~0d enolgy expe~ure  0bsel'v0d in 
CHF- 
~ In~'flml~ Insulin and Glt~'o~ in L IN I I | I  Heart 
FIIlum (NF) 
N, Sl~kln, R,S, McKeh~. J, Roulnau, C, Slga~n, E Wm~:ek, S. Yusut 
~ ~ Month~l Heart mtr~te Montreal, Can~ 
~:~g~¢~:  AIl~Om~Mit~ Of g~go~e (G) and insulin (I) me,alarum may 
play a role in tt~ etlolog~ and [~resso l  0t HF This Shx/¥ examnad me 
prl~#lence and cknical cowelatmn of O and t abnon'nalities m a stal~le HF 
mhofL 
,q~th~/s- FaM~ G and I ~ were obtained on 664 HF pahenls age 
(sd) 64 (10), EF ~ (?), NYHA.FC 1/11.64%, III/1V-36% 
R'eeu,~ 177 patmnts (2?%) wore known to have ~tes  me,~tus (DM) 
O~ the remaining 487 paltents, 111 (2"~ ~-) had eke'sled G (>6.t raM), w~lh 
53 (11%) in the DM range (G ~70 raM) In patients w~hout known DM: the 
mean Go I (sd) Im,.els and faslmg insultn rasmfarce mde~, (FIRt = G . I,'25) 
were 5-8 (2) raM, 13.3 (19) mUlL and 3 7 (8) (normal (sd), I = 4 (7) mU/L, 
FIRI ,, 1.4 (1)), G and I levels ~ ~ m palmnts with NYHA ~1111nan 
NYHA ~11. In addition, a greater I ~  o~ patients wan NYHA ~111 had 
DM than NYHA <_ IL (Table) 
mlhoul DM DM n (%i 
G (so') mM I (-~t mU/L FIRI (~1) 
NYHA -_1! ,5.611 0)" 102 t10 1)" 24 (2 8)" 100 (24)'" 
NNHA ~ III 63 t21) 196 (29,6) 6 2 (12 5) 77 (32l 
"p < 00001 (lOg clara). --p = 0 04 NYHA ~ II VS NYHA :lit 
C~'~:/usm~: G and I abnormalff~es are common in HF patmnts and appea~ 
to women as HF symptoms increase_ Tl~s suggests that abr~rmalmes of G 
or I are e~her a consequence of a pred~or of worsening symptoms of HF 
Furlhe~ study is needed to explem the role Of G and I abnon'naJilms in HF 
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Back~ound: We pfevrously reported that cardrac IToponin T (Tnrl @elected 
by second generatmn assay elevated in l:~1~ents wTth severe chron¢ heart 
failure (CHF) and suggested that latent ~ myocaro~al damage generated 
in severe CHF patients. In the present study, we tested the hypothesis that 
TnT would be a prognostic marker ol CHF 
Methods.- We measured serum second generation TnT levels (Boehnnger 
Mannheim) in 50 patients with CHF and investigated the relationships be- 
tween cardiac event (death or admission because ot worsening CHI c) and 
TnT levels and other climcal parameters (NYHA class. CTR. LVEF and atnal 
natnuretic peptide level). 
Results: Over a follow-up of 3 ~ 27 months. 7 patients were died and 
9 patients were readmitted because of worsening CHF All died patients 
showed TnT ~0.04 ng/mL Cardiac event-free rate in patients w~th TnT 30.05 
rig/mr was signitmantly lower than that in patients w~th l"nT ~005 ng/ml (1 
year 27.3 vs 82.6%, p = 0.0003). In a multtvanate Cox properbonal hazard 
analysis, NYHA class (p = 0.02) and TnT ~-005 ng/ml (p = 0.002) were. 
significantty and independently correlated to cardiac event-free ~ate 
Conclusion: The present study suggests that elevated TnT level ~dentifies 
patients at increased risk of cardiac event. 
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Background: Expenmental data in heart failure models, short term infusion 
m human congestive hear1 failure (CHF) and an open thai m pabems ~,tn 
idiopathic dilated card0omyopathy have demonstrated benet:oal effect: ol 
growlh hormone (GH) on cardiac lunctton 
Moth~tq Twenty I:~tmnts wffh mdd-moderale CHF (NYHA ClS~ It-II1! ot 
~chemtc (n = 8) or non . l~  (n = 14) OtK~gY, aed an ~ ttaclmn 
.45% were etuclH~ *n e 3 months double-blind and I~¢ebO contmae¢l real 
with recombinant hgman GH (thGH), They mcetyed e~er  ptacet~ (n ,= 10) 
or rt~;H (n ~ t0) in a dose 0! 0,! IF../kg/week for 1 week, end thema~ 
0,25 l ~ k  of # meslmel ~ i ly  ~ of 2 IE l ! ~ ,  Cafdmc 
hJfCtiofl wea ¢~termine¢l by (~Cluifltm~m ~ angiogtaphy at ~ 
e~ecme, and by 0oppler,eChccardiogm~y m rest, A ~m~l emil t~vcJe 
ex~se test and Ho~r ECG ~m 8~h~o ~m4 Pal~t~ were evaluatea t O, 
2 and 12 weeks afar ra~tat~n,  mspectNety 
Resu/M Them was a signltlcanl i ~  . I  insulin like growlh ta¢~ I O! 
140% m the GH group at 3 monthe compcq~ Io ~h~_-q~!ina, F~cellent p,~mm 
comp*~,c@, no ~ s  adveme eveme and no ~gmfcant i ~  in vem~c, 
ular army~mlas in the GH grote, ~red  to placebo were found, However 
no significant effect o! d~GH on systol~ Or ~¢¢ hmctlon, or maximal ex, 
e~se  capacity were found. Neither did NYHA hmct~nai ¢la~7.atK)n nor 
~rade ,n~rove 
ConctuSK~: Th*s ,s the first double blind and placebo controlled stuo'y o! 
long 8me rhGH adrninislratmn m pat~'nts ~ CHF ot dtflemm et~ologms 
The treatment was safe and w~mul senous adverse events However no 
po~dwe cardiac effecls were found. 
~ Sponlaneous Nocturnal Growth Hormone (GH) 
SecreHon and t!mm~ly~mk: Profile in Chronic 
Heart Failure (CHF) PMkmts 
M Vofterran,. A_ G~ustma ~. R. Longing, A. Gmrdano. "S,~vamm Maugen" 
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Endocnnotogy dep. Ira~y: "~ Spedall Cw~h d* gresOa, Cam~surgery It dep. 
Baotgroun.2 CHF ~s charactensed by acttvatmn of neursendoome system 
proport~nal 1O climcal seven~/, In urneared CHF pts GH level was found 
t~jher than in nomnal sub,~'ts NO data am available on GH eecretmn pm~le 
in trealed pts with severe hearl fa~ure. A~m of our study was Io assess: t ) 
GH sec~tmn nocturnal profile rn CHF pts m c,..~l.,ansen to normal su0fects 
2) ~ relatmnshq3 belween GH, insulin gmwlh factor 1 IGF.1. noradranaline 
NA. ad~enaflne A. a~nal natnurebc taclor ANP and the haemodynaro~ profile 
rn m~S pts. 
Meff/o:/s: In 7 noroval sul~ecls age-matched, and ~ 12 males, w~h 
~schaem¢ CHF, mean age 63 : 7. mean EF (ECHO) 20.6 ~ 65%, m ~able 
standard chronic merapy we evaluated overn~ghl (evew 20 mm from 10 pm 
to 6 am.) spontaneous GH secret~ (IRMA. N¢t'~s), baseline IGF-t (RIA, 
N'~'hols~ after ac~d-ettlanot extraction} and, only mplS, neuroendocllne pro~le 
and haemodynarmc parameters wa Swan*Ganz nghl hear cathefenzatlonr 
Results Th~ mean nocturnal GH level iS h*gher m pts compared w~ 
control group (1.4 ~ 0.6vs2.5 ± 13). We d~ net found any differences 
re* tGF-I level between the two groups. Accondmg w~th ~ aub~ GH 
mean nocturnal value, percents were d~ded in two subgroups (5 pls vs 7 
10is). Those with higher me~ spontaneous GH level (3.3 • 1 1 vs IA  t 
0.8 u/I) have lower IGF-1 level (119 ± 63 vs 2368 ± 35.9 ud) and a worse 
haernodynamic profile (mean PAP 44 ± 6 vs 30 ~: 10 mmHg; PCWP 29 ± 6 
vs 17 ± 7 mmHg; CO31 ± 1 vs4.8 -+ 1 L, Ynm; PVR440 ± 138 vs 267 :~ 123 
dme/cm2/sec-5) and higher symphatettc actnration (NA 734 + 303 vs 436 ± 
132. A88 ~ 60 vs60 ± 34, ANP 344 ± 184 vs 214 ± 174), 
Conc/us~ts: Our results shown that 1) CHF parleys shown on average 
a higher nocturnal GH secretion respect to normal subjects 2) among this 
patients, those with normal GH nocturnal secretion have luss severe haemo- 
dynamic picture and reduced sympathetic hyperactivation secretion respect 
to normal sublects 2) among this patients, those w~th normal GH nocturnal 
secretion h;~ve 10.% severe heemodynamic prcture ~nd reduced sympathetic 
hyperactreation. 
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It has been shown that in chronic head failure (CHF). respiratory disorders 
such as Cheyne-Stokes (CS) and periodic breathing !PB). which are a fte- 
quent event during sleep, may occur even dunng day-time in patients [gts) 
with compensated heart failure. These alterations of breathing cause further 
ventricular impairment and sympatt'mtic hyperaclivation, but their impact on 
survival is still debated. To address the assooation between awake breathing 
disorders and shod-term prognosis 15- = moderate to severn CHF pts (mEan 
